Navidea's Macrophage heralds preclinical drug conjugate for Kaposi's sarcoma; Biogen links up with AGTC on blindness gene therapy;

> Macrophage Therapeutics, part of Navidea ($NAVB), announced preclinical results from its study of doxorubicin linked to its drug conjugate Manocept as a treatment for Kaposi's sarcoma. Release

> Biogen ($BIIB) and AGTC have joined forces to develop gene therapies for ophthalmologic use. AGTC's main foci are diseases of the retina that can lead to blindness. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.